Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Novartis, Variagenics Ink Prostate-Cancer Pharmacogenomics Deal

NEW YORK, May 2 - Variagenics said today it will study the pharmacogenomics of two of Novartis' prostate-cancer drug candidates.


Variagenics will use its platform to identify drug-efficacy markers for two compounds, Gleevec and PKI 166.


Novartis gets an exclusive license to any therapeutic markers, and Variagenics retains rights to develop DNA diagnostic tests.


Click here for more information.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.